RIMACTANE Drug Patent Profile
✉ Email this page to a colleague
When do Rimactane patents expire, and when can generic versions of Rimactane launch?
Rimactane is a drug marketed by Oxford Pharms and is included in one NDA.
The generic ingredient in RIMACTANE is rifampin. There are nine drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the rifampin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rimactane
A generic version of RIMACTANE was approved as rifampin by EPIC PHARMA LLC on May 28th, 1997.
Summary for RIMACTANE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 47 |
Clinical Trials: | 7 |
Patent Applications: | 6,837 |
Formulation / Manufacturing: | see details |
DailyMed Link: | RIMACTANE at DailyMed |
Recent Clinical Trials for RIMACTANE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Cape Town | Phase 3 |
Epizyme, Inc. | Phase 1 |
University of Cape Town | Phase 1 |
US Patents and Regulatory Information for RIMACTANE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oxford Pharms | RIMACTANE | rifampin | CAPSULE;ORAL | 050429-001 | Approved Prior to Jan 1, 1982 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |